Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Exelixis
National Cancer Institute (NCI)
Amgen
EMD Serono
The Methodist Hospital Research Institute
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Bayer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sotio Biotech Inc.
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Rondo Therapeutics
Bayer
Mayo Clinic
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Memorial Sloan Kettering Cancer Center
Emory University
M.D. Anderson Cancer Center
Pfizer
Seagen Inc.
Incendia Therapeutics
Tizona Therapeutics, Inc
Shanghai Henlius Biotech
Amgen
University of Rochester
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Novartis
Bio-Thera Solutions
AbelZeta Inc.
TILT Biotherapeutics Ltd.
Amgen
Sairopa B.V.
Rutgers, The State University of New Jersey
Abramson Cancer Center at Penn Medicine
Cullinan Therapeutics Inc.